We have earlier described the oncolytic adenovirus vector dl520 that was rendered cancer-specific by deletion of the transactivation domain CR3 of the adenoviral E1A13S protein; this deletion causes antitumor activity in drug-resistant cells displaying nuclear YB-1 expression. We hypothesized that the anticancer activity of dl520 could be further improved by introducing the RGD motif in the fiber knob and by deletion of the adenoviral E1B19K protein (Ad-Delo3-RGD). In this study, the in vitro and in vivo antitumor activity of Ad-Delo3-RGD was investigated focussing on two pancreatic cancer cell lines MiaPaCa-2 and BxPC3 alone and in combination with cytotoxic drugs. Furthermore, luciferin-based bioluminescence imaging was established to study the therapeutic response in vivo. In addition, to confirm the specificity of Ad-Delo3-RGD for YB-1 a tetracycline-inducible anti-YB-1 shRNA-expressing cell variant EPG85-257RDB/tetR/YB-1 was used. This TetON regulatable expression system allows us to measure adenoviral replication by real-time PCR in the absence of YB-1 expression. The results confirmed the YB-1 dependency of Ad-Delo3-RGD and showed that Ad-Delo3-RGD has potent activity against human pancreatic cancer cells in vitro and in vivo, which was augmented by the addition of paclitaxel. However, although high replication capacity was measured in vitro and in vivo, complete tumor regression was not achieved, indicating the need for further improvements to treat pancreatic cancer effectively.
Introduction
Replication-selective oncolytic adenoviruses represent a novel, targeted class of therapeutic agents that are being developed for the treatment of cancer. These agents propagate selectively in tumors and lyse them without causing excessive damage to normal non-cancerous tissues. 1 Several viruses with different tumor-specific selectivity strategies have been developed, including the use of tumor-specific promoters and the deletion of viral genes that are critical for efficient viral replication in normal cells, but dispensable in tumor cells. Examples include dl922-947, where the E1A binding to the retinoblastoma protein is disrupted, and p53-defective adenovirus, such as dl1520 (Onyx-015). 2, 3 However, our strategy is on the basis of the multifunctional protein YB-1, which is involved in transcriptional and translational regulation, mRNA splicing, drug resistance and DNA repair. 4 We could earlier show that YB-1 facilitates E1-independent adenoviral replication by targeting the adenoviral E2-late promoter. 5 The significance of YB-1 as a key regulatory molecule for adenoviral replication was supported in other studies using dl520, an E1A-mutated adenovirus lacking the E1A13S protein, which replicates in multidrug-resistant cancer cells in which YB-1 is located in the nucleus. 6 Furthermore, we showed that an E1-deleted adenoviral vector expressing YB-1 as a transgene has the ability to replicate and to produce infectious particles. 7 To further improve the potential of oncolytic adenoviruses, different approaches have been developed including insertion of the integrin-binding motif, RGD, allowing CAR-independent (Coxsackie adenovirus receptor) infection. 8, 9 As flow cytometry revealed low CAR expression in many pancreatic cancer cell lines, targeting integrins has shown a dramatic enhancement of adenovirus infection. 10 In addition, the deletion of the adenoviral E1B19K protein, a Bcl-2 homolog that blocks apoptosis induction, has been shown to increase viral spread resulting in significant antitumoral efficacy. 11 Hence, we developed an enhanced version of dl520 termed Ad-Delo3-RGD with deletions in the e1b19k and E3 region and with an RGD motif in the fiber protein and analyzed its oncolytic potential.
Although oncolytic adenoviruses exert anticancer activity by killing infected cancer cells as part of the process of adenovirus replication, low efficacy has been reported frequently when used as single modality. Favorable interactions of oncolytic Ad with different cytotoxic drugs have been reported, including temozolomide, 5-fluorouracil, cisplatin, irinotecan and paclitaxel. 12 As YB-1 plays an essential role in the adenoviral life cycle and is involved in the drug-resistant phenotype of tumor cells, we examined the oncolytic potential of Ad-Delo3-RGD in combination with cytotoxic drugs in human pancreatic cancer cells in vitro and in vivo. Although less is known about YB-1 expression and localization in pancreatic cancer, we choose this malignancy because it is highly resistant to radiation and chemotherapy and has only a dismal 5-year survival rate of o5%, 13 implicating the need for new therapeutic interventions. The feasibility and safety of oncolytic virus therapy for pancreatic cancer treatment has been shown by two clinical studies with Onyx-015. 14 In addition, this work showed that transgastric endoscopic ultrasound guided oncolytic virus injection is a well-tolerated and practical method of delivering biological agents into pancreatic tumors. 15 To address the YB-1 dependency of Ad-Delo3-RGD, we used an established tetracycline-inducible anti-YB-1 shRNA-expressing cell variant EPG85-257RDB/tetR/ YB-1. 16 The drug-resistant cell line EPG85-257RDB is characterized by its high CAR expression and the presence of nuclear YB-1 (because of cultivation in the presence of the cytostatic drug daunorubicin). Thus, this TetON regulatable expression system allows us to measure adenoviral replication by real-time PCR in the absence of YB-1 expression. Finally, in vivo bioluminescence imaging of luciferase-transfected pancreatic cancer cells was established to investigate the dynamics of tumor growth and to assess the efficacy of our treatment regimen in a pancreatic xenograft model.
Materials and methods

Cell lines and culture conditions
The human pancreatic cancer cell lines Capan-1, Hs766T, DanG, MiaPaCa-2 and BxPC3 were grown in Dulbecco's Modified Eagle's Medium containing 10% fetal calf serum and 2% L-glutamine. MiaPaCa-2 and BxPC3 expressing a fLuc gene were generated as published. 17 HeLaP was cultured in Dulbecco's Modified Eagle's Medium containing 10% fetal calf serum and 2% L-glutamine. The multidrug-resistant HeLaRDB and the human gastric carcinoma cell line EPG85-257RDB were established by in vitro exposure to daunorubicin (Farmitalia Carlo Erba, Freiburg, Germany). Both cell lines were grown in Leibovitz's L-15 medium supplemented with 10% fetal calf serum, 2% L-glutamin, 80 IE l
À1
Insulin and 0.25 mg ml À1 daunorubicin. Establishment and characterization of the tetracycline-inducible anti-YB-1 shRNA-expressing cell variants EPG85-257RDB/tetR/ YB-1 was described earlier. 16 
Adenoviral vectors
Ad-Delo3-RGD was constructed by subcloning dl520 DNA from SspBI (Ad-WT position) nt193 to MunI nt3925 into the shuttle plasmid of the AdEasy system (Qbiogene, Montreal, Canada). E1B19K was partly deleted by restriction with EcoNI at nt1715 and BstEII at nt1916, without affecting the open reading frame of e1b55k. Homologous recombination with the RGDmodified AdEasy backbone as described resulted in AdDelo3-RGD.
18
Dl312 is a E1A-deleted adenovirus. 19 Ad-Delo3-RGD, dl312 and Ad-WT were produced in HEK 293 cells (Clontech, Mountain View, CA) and purified by two consecutive iodixanol gradient centrifugations and additionally by size-exclusion chromatography (Disposable PD-10 Desalting Columns, GE Healthcare, Freiburg, Germany). 20 To exclude contamination of Ad-Delo3-RGD by Ad-WT and to verify the viral construct PCR against e1a13s, e1a12s, e1b19k and RGD was performed (E1A13Sfw: Quantification of virus replication in vitro by real-time PCR after YB-1 inhibition To investigate the influence of nuclear YB-1 in viral replication, we used a tetracycline-inducible anti-YB-1 shRNA-expressing cell variant EPG85-257RDB/tetR/ YB-1. At 4 days before infection with indicated multiplicity of infection (MOI) 2 mg ml À1 tetracycline (Invitrogen, Karlsruhe, Germany) was added to induce anti-YB1 shRNA expression. After 72 h, DNA was isolated and its concentration was measured thrice photometrically. For quantitative viral replication analysis, a real-time PCR protocol was applied using a LightCycler instrument and SYBR-Green fluorescent dye (Roche Diagnostics, Mannheim, Germany), as described earlier. 16 Specific primers used for amplification of adenoviral DNA were: Hexon-fw Cytopathic effect assay For determination of virus-mediated cell killing, cells were seeded in 12-well plates at a density of 1 Â 10 5 per well. Cells were infected with Ad-Delo3-RGD at indicated MOI in 150 mL Opti-MEM. At 1 h after infection, Opti-MEM was replaced with complete medium. Cells were fixed after 4 days with 10% trichloro acetic acid overnight at 4 1C and stained with 0.5% sulforhodamine B in 0.1% acetic acid, followed by washing with 1% acetic acid to remove excess of color. Quantification was done by photometric measurement at 590 nm after dissolving dried sulforhodamine B with 10 mM Tris buffer (pH 10). In terms of the combination therapy with cytostatic drugs, cells were treated 4 h before infection with Ad-Delo3-RGD.
Southern blot analysis
Replication analysis was carried out on MiaPaCa-2 and BxPC3 cells (2 Â 10 5 per well) in 6-well plates infected with adenovirus vectors at different MOI and incubated with indicated paclitaxel concentrations. DNA was isolated 48 h after infection and 2 mg from each sample was digested with the restriction endonuclease KpnI, size was fractionated on a 1% agarose gel, transferred to a nylon membrane using the Turboblotter Rapid Downward Transfer System (Schleicher & Schuell, Dassel, Germany) and hybridized with a specific 32 P-labeled E2late probe. 6 Immunohistochemistry For immunohistochemistry analysis cells were grown on slides, fixed for 10 min in a methanol/acetone (1:1) mixture at -20 1C and then air-dried. Immunohistochemical reactions were done with the primary antibody rabbit anti-YB-1 (Abcam, Cambridge, UK). The antigens were visualized by fluorescence using biotinylated secondary antibodies (Dako, Hamburg, Germany), streptavidin-FITC (Invitrogen) complex. Slides were counterstained with Hoechst staining (Sigma, Taufkirchen, Germany) and mounted with vector shield (Vector Laboratories, Burlingame, CA). Images were taken with fluorescence microscope ApoTome Imaging System (Zeiss, Oberkochen, Germany).
In vivo animal experiments
Xenografts were established in 6-week-old BALB/c nu/nu mice (Charles River, Sulzfeld, Germany) by injecting 1 Â 10 6 MiaPaCa-2 cells in 100 mL 0.9% NaCl (Delta Select) mixed with 100 mL Matrigel (BD Biosciences, Heidelberg, Germany) s.c. into the right flank. MiaPaCa-2 cells were chosen for the xenograft model because of its resistant phenotype against paclitaxel in vivo. Tumor size measurement was done twice weekly in three dimensions by external calliper. About a mean volume of 240 mm 3 , mice were randomized into four groups with 9 to 11 animals in each group. On day 2, 5 and 8 the first group received 200 ml PBS intratumoral and the second group received Ad-Delo3-RGD with a dose of 2 Â 10 8 pfu in a volume of 150 ml per injection intratumoral. The third group received 2.5 mg kg À1 paclitaxel i.p. on days 1, 4 and 7 with a total dose of 7.5 mg kg
À1
. The last group received a combination of virus and paclitaxel.
The statistical analysis, including means and standard deviations as well as median values, was carried out using SPSS software (version 15.0; SPSS, Inc. Chicago, IL). To analyze exponential tumor growth, expansion rates were calculated by log-linear regression models. Overall comparisons of measurements between more than two independent groups were carried out using KruskalWallis rank test followed by Mann-Whitney-U twosample comparisons. All analyses were carried out twosided at a 5% level of significance. Bonferroni correction of alpha error level was additionally conducted in case of multiple testing considering significant results by chance.
In vivo bioluminescence imaging Bioluminescence imaging was carried out 1 week before treatment and 6 and 13 days after last treatment. Mice were anesthetized with Domitor/Fentanyl/Midazolam (1:2:2), injected with d-luciferin (Synchem, Kassel, Germany) at 50 mg kg À1 i.p. and imaged after 7 min using a cooled backthinned, charge-coupled device camera (IVIS Imaging System100 Serie, XENOGEN, Alameda, CA).
Assessments of in vivo replication of Ad-Delo3-RGD To obtain information regarding the replication efficacy and biodistribution of Ad-Delo3-RGD, DNA from the tumor and liver tissue was isolated on completion of the in vivo experiment using standard protocol. Concentration was measured thrice photometrically. For quantitative viral replication analysis, a real-time PCR protocol was applied using a LightCycler instrument and SYBR-Green fluorescent dye (Roche Diagnostics) as described above.
Results
Characterization of Ad-Delo3-RGD To verify the genome of Ad-Delo3-RGD (Figure 1a ) with regard to the specific deletions and the RGD motif, PCR with specific primer was performed. As shown in Figure 1b Ad-Delo3-RGD did not feature the E1A13S and E1b19k corresponding genes. In addition, the PCR confirmed the inclusion of the RGD motif.
YB-1 dependency of Ad-Delo3-RGD
To show the YB-1 dependency of Ad-Delo3-RGD, the viral hexon DNA production after replication with one and five MOI in EPG85-257RDB/tetR/YB-1 was measured by real-time PCR. Knock down of YB-1 with shRNA, which was verified by western blot analysis 16 and immunohistochemistry (data not shown) decreased significantly the viral replication at one MOI by 69.9% and at five MOI by 57.1%, showing the high YB-1 dependency of Ad-Delo3-RGD (Figure 2) . Similar results were YB-1 mediated virotherapy E Rognoni et al obtained using two additional YB-1-dependent oncolytic adenoviruses dl520 21 and XVir03 22 (data not shown). The following experiment addressed the question of whether Ad-Delo3-RGD displays specificity for MDR tumor cells with nuclear localization of YB-1 in contrast to Ad-WT. Therefore, we used HeLaP and the isogenic MDR cell line HeLaRDB for CPE analysis. One MOI of Ad-WT was sufficient to kill all HeLaP and HeLaRDB cells, showing that Ad-WT exhibits no selectivity. In contrast, the YB-1 dependent-adenovirus Ad-Delo3-RGD was not able to induce any CPE in HeLaP up to 10 MOI. In HeLaRDB on the contrary one MOI of Ad-Delo3-RGD killed 50% of the cells and five MOI induced nearly 100% CPE (data not shown). 
YB-
1 mediated virotherapy E Rognoni et al
YB-1 expression and localization
Owing to the fact that Ad-Delo3-RGD depends strongly on the cellular transcription factor YB-1, we investigated its expression and localization in the pancreatic cell lines MiaPaCa-2 and BxPC3 ( Figure 3 ). In MiaPaCa-2 and BxPC3 cells, YB-1 was highly overexpressed and mainly located in the perinuclear space and to less extent in the nucleus. In contrast to the resistant HeLaRDB cells in which YB-1 staining in the nucleus seemed spottier, the staining pattern in the pancreatic cells seemed more homogeneous. The cause of those differences is currently not clear and requires further studies.
Cell killing and viral replication
Next, we asked whether Ad-Delo3-RGD is able to replicate and to induce CPE in several pancreatic cell lines. Replication was investigated by Southern blot analysis. As shown in Figure 4 at five MOI only Ad-WT and Ad-Delo3-RGD but not the E1A-deleted dl312 were able to replicate in all pancreatic cell lines. Furthermore, our results showed that Ad-Delo3-RGD at low MOI displays a high lytic capacity in MiaPaCa-2 and BxPC3 cells. Ad-Delo3-RGD caused nearly complete cytolysis at 10 MOI. At five MOI only 20% of MiaPaCa-2 and 40% of BxPC3 were able to survive (Figure 5a ).
Combination therapy
Furthermore, we sought to evaluate the cytotoxicity of the virus in combination with paclitaxel. MiaPaCa-2 cells were treated with 40 and 60 nM paclitaxel for 4 h before infection with indicated MOI and CPE was determined. As shown in Figure 5b , combined treatment with 40 nM paclitaxel and 2.5 MOI Ad-Delo3-RGD led to 20% survival of MiaPaCa-2 cells compared with 90% in the viral and 80% in the paclitaxel control group. Thus, the combination of paclitaxel with Ad-Delo3-RGD caused enhanced cell lysis, indicating that a combination of chemotherapy and
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HeLaP
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BxPC3
MiaPaCa-2 Figure 3 Immunohistochemistry of YB-1 in BxPC3 and MiaPaCa-2. Cells were treated with a polyclonal rabbit anti-human YB-1 antibody and counterstained with Hoechst. Fluorescence images were taken at a magnification of Â 64. HeLaP and HeLaRDB cells served as controls.
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Ad-Delo3-RGD infection is significantly more efficient in cell killing than both treatments alone. In regard to these results, we were interested whether the observed enhanced CPE also correlates with an increase of Ad-Delo3-RGD replication in MiaPaCa-2 cells. For this purpose, cells were treated for 1 h with the indicated paclitaxel concentrations before infection with four MOI Ad-Delo3-RGD. As shown in Figure 5c , increasing concentration of paclitaxel led to a significant dose dependency increase of Ad-Delo3-RGD replication compared with untreated infected cells.
In vivo growth inhibition
On the basis of our encouraging in vitro results, we decided to establish a xenograft pancreatic tumor model for a combination therapy with Ad-Delo3-RGD and paclitaxel. In this explorative study tumor growth was monitored for 18 days after treatment ( Figure 6 ).
Mean tumor growth per day amounted to 9.5% ± 4.3 in the PBS group (median: 7.3%; IQR (interquartile range): 6.0% to 12.7%), 7.3%±2.9 in the paclitaxel group (median: 6.6%; IQR: 5.5%-8.0%), 3.7% ± 3.6 in the virus monotherapy group (median: 4.6%; IQR: 1.2% to 6.7%) and À1%±5.7 in the combination therapy (median: þ 1%; IQR: À5.3% to 4.1%).
Thus, mean tumor growth rates of the PBS and the paclitaxel group were similar, indicating that Paclitaxel single treatment was not effective in the used dosage. Instead, virus monotherapy led to a significant reduction of the mean tumor growth rate at the 5% level, but not at the adjusted significance level of 0.008 (virus vs combination: P ¼ 0.010; virus vs paclitaxel: P ¼ 0.034). With dual therapy, a significant Figure 4 Replication analysis in pancreatic tumor cells. Cells were infected with five multiplicity of infection (MOI) with indicated virus. DNA was isolated after 48 h and subjected to Southern blot analysis. An E2A-PCR probe was used to indicate the amplification of adenoviral DNA in infected cells. 
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E Rognoni et al tumor growth reduction was obtained in contrast to PBS (Pp0.001) and paclitaxel single treatment (Pp0.001). In fact, before killing the mean tumor volume in the animals submitted to combination therapy was four times smaller than in animals treated with PBS. Combination therapy even led to a significant tumor growth reduction (P ¼ 0.024) at the 5% level compared with virus single therapy. Thus, in line with our strategy the combination therapy resulted in an increase of the oncolytic effect in vivo.
In addition, imaging studies on several animals of all treatment groups confirmed that only the virus-and combination-treated groups showed a decrease in luciferase signal, indicating that Ad-Delo3-RGD inhibited tumor growth significantly (Figure 7 ).
Paclitaxel does not improve viral replication in vivo
For further investigation of the efficacy enhancement by paclitaxel in response to Ad-Delo3-RGD, we determined replication levels in MiaPaCa-2 tumors from athymic mice by real-time PCR. In contrast to the in vitro results, we did not observe a significant increase in viral replication in the paclitaxel-treated group (Figure 8) . A testing for virus in liver tissue of the virus/paclitaxeltreated animals revealed the absence of viral DNA.
Discussion
With the development of Ad-Delo3-RGD, we follow a strategy on the basis of the upregulation and nuclear localization of YB-1 in different types of cancer. It becomes more and more evident that the multifunctional protein YB-1 displays oncogenic properties and promotes drug resistance in several solid tumor types. 4 More recently, further cellular regulatory mechanisms, such as mRNA stability and translation, have been reported for YB-1. 23 The discovery that YB-1 is most likely a key component in the adenoviral life cycle encouraged us to generate a selective oncolytic virus, which preferably replicates in YB-1 overexpressing cells. To verify the specificity of Ad-Delo3-RGD, we used a tetracycline-inducible anti-YB-1 shRNA-expressing cell variant EPG85-257RDB/tetR/YB-1. 16 YB-1 knock-down in EPG85-257RDB/tetR/YB-1 led to reduced YB-1 mRNA and protein levels as reported before. This inducible system allowed us to verify a significant YB-1 dependency of Ad-Delo3-RGD replication (Figure 2 ). However, we did not observe complete inhibition of viral replication. This might be explained by the fact that inducible shRNA-mediated targeting YB-1 not completely abolished YB-1 expression, which otherwise would lead to cell death. 24 To further confirm the YB-1 dependency, we compared the selectivity of Ad-Delo3-RGD in the parental cell line HeLaP and the resistant YB-1-positive counterpart HeLaRDB. In fact, high CPE could be observed in the infected HeLaRDB cells, establishing the selectivity of Ad-Delo3-RGD for cells with nuclear YB-1 localization (data not shown). The results remain to be verified in a pancreatic cancer background as well.
Although the replication capacity was comparable to wild-type adenovirus (Figure 4 ), we observed a 10-50 times lower particle formation (data not shown). The 25, 26 Therefore, we tested chemotherapeutic agents in vitro, which are Figure 8 Real-time PCR analysis of tumor and liver tissue of indicated treatment groups. DNA from tumors and some liver samples from the virus/paclitaxel treatment group (V þ P) were isolated on completion of the in vivo experiment using standard protocols. Concentration was measured thrice photometrically. Hexon copy numbers per microgram DNA is shown. The experiment was repeated thrice independently.
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13 days pt. Figure 7 In vivo bioluminescence imaging before and after treatment with Ad-Delo3-RGD. Mice were imaged 1 day before treatment and 6 and 13 days after last treatment. Imaging conditions (f/stop: 8, binning: medium, exposure time: 1 min) were always the same. bf, before treatment; pt, post treatment.
YB-1 mediated virotherapy E Rognoni et al used in pancreatic cancer treatment like paclitaxel, gemcitabine, temozolomide and irinotecan. Paclitaxel potentiated the oncolytic effect of Ad-Delo3-RGD at least partly by enhancing the replication efficacy ( Figure 5 ). Gemcitabine, temozolomide and irinotecan led only to minor effects (data not shown).
It is interesting to note that there is growing evidence that paclitaxel enhances viral oncolysis on different fronts, but the underlying mechanisms still remain unclear. Nielsen LL et al. 27 reported that paclitaxel at low concentrations (1-14 nM) increased the number of cells transduced by recombinant adenovirus by 3-35% in a dose-dependent manner. Furthermore, in non-small cell lung cancer AbouEl Hassan MA et al. could show that paclitaxel potentiated the adenoviral oncolysis synergistically. The co-treatment with 50 nM paclitaxel increased the expression level of e1a13s, adp and penton genes, which correlated with an increase in viral particle assembly and release. 28 Numerous investigators have shown that the E1A protein alone is important for sensitization to cytotoxic agents. A recent report has shown that E1A levels were elevated in response to chemotherapeutics. Overall combined treatment of cytostatic drugs and oncolytic adenovirus might be dependent on several factors in a complex manner. The finding of Fujita et al., 29 who could show in breast cancer cells that YB-1 is translocated to the nucleus after paclitaxel treatment is in line with our hypothetic model termed Mutually Synergistic Therapy (MUST). 22 This may contribute to the enhanced oncolytic potential of AdDelo3-RGD in combination therapy too. However, it is still unknown, how YB-1 is translocated into the nucleus. This may be accomplished by different mechanisms. 30 Nevertheless, nuclear translocation of YB-1 caused by environmental stress factors seems to be a general activation mechanism of YB-1. As YB-1 is a downstream target of the PI3/AKT and STAT3/TWIST oncogenic signaling pathways, [31] [32] [33] [34] which plays key roles in fundamental cellular processes, including proliferation, drug resistance and apoptosis, it would be of great interest to combine YB-1-based virotherapy approach with inhibitors of those pathways such as the protein kinase c beta selective Inhibitor Enzastaurin, which suppresses signaling through the AKT pathway 35 and Iressa, which inhibits TWIST expression. 36 Nevertheless, the role of YB-1 still remains to be elucidated in depth in pancreatic cancer.
However, in view of the in vitro results, we decided to test a combination therapy of Ad-Delo3-RGD and paclitaxel in a pancreatic xenograft model. Virus monotherapy slowed down tumor growth significantly compared with the control. It is interesting to note that whereas the chosen paclitaxel dosage alone was inefficient, the dual treatment potentiated the tumor regression further without enhancement of replication (Figure 8) . A possible reason for the lack of increased viral replication might be the late time of DNA isolation from the tumor, and thus we can not completely exclude increase of viral replication at an earlier time point as observed in vitro. Although we observed strong replication in the tumor without any sign of spread to the liver, we did not observe complete tumor regression. Luciferase-based imaging confirmed those results, showing a re-growth of the tumor. Together, the results indicate that our strategy probably also faces similar drawbacks as comparable strategies concerning limited viral spread. It is obvious that alternative strategies are required to circumvent this problem. Thus, establishing a treatment protocol, which would enhance viral spread by degrading the extracellular matrix, might be mandatory to achieve the full potential of YB-1-based virotherapy. The utility of such an approach using hyaluronidase has recently been shown by Ganesh et al. 37 Another reason is surely the host's immune response. Recent results have shown that additional treatment with low-dose cyclophosphamide, which causes among other things elimination of regulatory T cells in a corresponding mouse model is beneficial for improving the efficacy of virotherapy. [38] [39] [40] In summary, our study is the first to show that YB-1-dependent virotherapy in combination with chemotherapy is an attractive treatment option for pancreatic cancer. We observed high replication potency in vitro and in vivo. However, further substantial in vivo studies are required to find an effective therapeutic protocol for this combination therapy in the treatment of pancreatic cancer. Especially, a comprehensive analysis regarding YB-1 expression in normal pancreatic tissue together with the influence of paclitaxel treatment is required before a clinical trial. Finally, the results of this study give a rationale for testing this approach in combination with depletion of regulatory T cells and proteolytic enzymes to improve future YB-1-based virotherapy regimens.
